BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 1100294)

  • 1. A field with a liver measles-mumps-rubella vaccine.
    Walters VW; Miller SA; Jackson JE; Kenny MT
    Clin Pediatr (Phila); 1975 Oct; 14(10):928-33. PubMed ID: 1100294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of a new measles-mumps-rubella combined live virus vaccine in the Dominican Republic.
    Ehrenkranz NJ; Ventura AK; Medler EM; Jackson JE; Kenny MT
    Bull World Health Organ; 1975; 52(1):81-5. PubMed ID: 764997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evaluation of a new measles-mumps-rubella trivalent vaccine.
    Schwarz AJ; Jackson JE; Ehrenkranz NJ; Ventura A; Schiff GM; Walters VW
    Am J Dis Child; 1975 Dec; 129(12):1408-12. PubMed ID: 128287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence of antibody after administration of monovalent and combined live attenuated measles, mumps, and rubella virus vaccines.
    Weibel RE; Buynak EB; McLean AA; Hilleman MR
    Pediatrics; 1978 Jan; 61(1):5-11. PubMed ID: 263873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of live trivalent vaccine of measles AIK-C strain, mumps Hoshino strain and rubella Takahashi strain, by virus-specific interferon-gamma production and antibody response.
    Nakayama T; Urano T; Osano M; Nakagawa M; Maehara N; Sasaki K; Yamamura AM; Makino S
    Microbiol Immunol; 1990; 34(6):497-508. PubMed ID: 2120551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trial of a new trivalent measles-mumps-rubella vaccine in young children.
    Vesikari T; Ala-Laurila EL; Heikkinen A; Terho A; D'Hondt E; André FE
    Am J Dis Child; 1984 Sep; 138(9):843-7. PubMed ID: 6383020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Experience with preventive measles, mumps and rubella vaccination in unified Germany].
    Gerike E; Tischer A
    Gesundheitswesen; 1993 Jan; 55(1):38-9. PubMed ID: 8435543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Certain problems with limits of immunity against measles, mumps and rubella].
    Magdzik W
    Przegl Epidemiol; 1993; 47(1-2):47-53. PubMed ID: 8351387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience with live rubella virus vaccine combined with live vaccines against measles and mumps.
    Smorodintsev AA; Nasibov MN; Jakovleva NV
    Bull World Health Organ; 1970; 42(2):283-9. PubMed ID: 5310140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Field trial with a new human diploid cell vaccine (HDCV) against measles, mumps and rubella].
    Just M; Berger R; Glück R; Wegmann A
    Schweiz Med Wochenschr; 1985 Nov; 115(48):1727-30. PubMed ID: 4081704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Conjugated vaccine against measles, rubella and mumps].
    Vopr Virusol; 1989; 34(1):117-9. PubMed ID: 2728403
    [No Abstract]   [Full Text] [Related]  

  • 12. Interference between strains in live virus vaccines, I: Combined vaccination with measles, mumps and rubella vaccine.
    Berger R; Just M; Glück R
    J Biol Stand; 1988 Oct; 16(4):269-73. PubMed ID: 3198657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration of measles-mumps-rubella vaccination with other childhood schedule vaccines.
    Heath TC; Burgess MA; O'Brien ED
    Commun Dis Intell; 1998 Aug; 22(8):159. PubMed ID: 9735551
    [No Abstract]   [Full Text] [Related]  

  • 14. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.
    Peltola H; Heinonen OP; Valle M; Paunio M; Virtanen M; Karanko V; Cantell K
    N Engl J Med; 1994 Nov; 331(21):1397-402. PubMed ID: 7969278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined trivalent and bivalent measles, mumps and rubella virus vaccination. A controlled trial.
    Swartz TA; Klingberg W; Klingberg MA
    Infection; 1974; 2(3):115-7. PubMed ID: 4606362
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinico-immunologic evaluation of a trivalent vaccine against measles, rubella and mumps].
    Schettini F; Manzionna MM; De Mattia D; Amendola F; Di Bitonto G
    Minerva Pediatr; 1989 Mar; 41(3):117-22. PubMed ID: 2747598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Morbidity, vaccine coverage and immunity against measles, mumps and rubella in a Gallician population from 2 to 5 years old].
    Vázquez Fernández E; López Rois F; Vázquez Carrete JA; Gómez Tato B; Alvarez Ares M
    An Esp Pediatr; 1987 Jul; 27(1):27-31. PubMed ID: 3662251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Vaccination rate for triple measles-rubella-mumps vaccine in Empoli Val d'Elsa area health district U.S.L. 11, Tuscany Region].
    Salvadori P
    Ann Ig; 1998; 10(1):19-24. PubMed ID: 9616974
    [No Abstract]   [Full Text] [Related]  

  • 19. A field trial of combined measles-mumps-rubella vaccine. Satisfactory immunization with 188 children in Chile.
    Borgoño JM; Greiber R; Solari G; Concha F; Carrillo B; Hilleman MR
    Clin Pediatr (Phila); 1973 Mar; 12(3):170-2. PubMed ID: 4701464
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination.
    Lerman SJ; Bollinger M; Brunken JM
    Pediatrics; 1981 Jul; 68(1):18-22. PubMed ID: 7017582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.